The next plague has already come. Covid can teach us how to stop.

For decades after penicillin was introduced, bacterial mutations and the availability of drugs combined, making antibiotics effective in the presence of pathogens. But by the 1970’s, the eruptions of the 21st century were coming to an end. Making antibiotics is difficult: these drugs should not be dangerous to humans but dangerous to bacteria, and they should use methods where harmful bacteria have not changed immunity. But getting rid of natural antibiotics and making drugs in the lab was very difficult.

Resistance, meanwhile, to jump forward. Excessive use of pesticides, agriculture, and aquaculture spread antibiotics through nature and allow germs to adapt. Between 2000 and 2015, the use of antibiotics stored for the most dangerous diseases almost twice worldwide. Controversial standards vary in body, drug, and location, but the most comprehensive report has been conducted so far, published June 2021 by WHO, shows how rapidly things have changed. Among other types of urinary tract infections, one of the most common problems in the world, some were resistant to common antibiotics up to 90% of the time in some countries; more than 65% of blood-borne pathogens and more than 30% of pneumonia-resistant bacteria also refuse one or more treatments. Gonorrhea, once a simple, curable virus that causes infertility if left untreated, is growing rapidly resistant to all antiretroviral drugs.

At the same time, antibodies — a gene that controls bacteria to protect themselves — are sweeping the globe. In 2008, a man from India was hospitalized in Sweden with a large number of bacteria with a genetic component that allows him to resist virtually all antibiotics. In 2015, British and Chinese researchers found genetics in pigs, pigs in markets, and hospital patients in China that allowed bacteria to break down colistin, known as end-to-end antibiotics to combat the most dangerous bugs. All of these organisms, which move from one bacterium to another, have spread around the world.

In the face of economic downturns, antibiotic research has not continued. In March, the Pew Charitable Tr trust tested the world’s pipeline for new antibiotics. Although the team found 43 elsewhere in the early stages or trials, it found that only 13 were third-party, two-thirds of which were able to issue a permit – and none had an anti-microbial molecule that was too difficult to treat.

Lessons learned from Warp Speed

So what does Operation Warp Speed ​​on antibiotics look like?

Antibiotic tubes need to be strengthened in a number of key areas: preliminary research, trial design, and post-approval interventions. Fortunately, the global response to covid produced models for all three.

The first step might be to help with the initial research. Moderna vaccine and Pfizer-BioNTech were ready for more than a year from the initial diagnosis of human disease. But that improvement came from 10 years of initial research without any specific diseases. As soon as Covid appeared, Warp Speed ​​brought the Moderna vaccine to an end with additional research costs. (Pfizer did not receive research support from Warp Speed, but both companies found funding for manufacturing and production.)